D
Dostarlimab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Medical Assistance Fund
Active ingredient: Dostarlimab
General information
Subsidy Information and Financing Scheme
[MAF] Dostarlimab [Jemperli] Concentrate For Infusion 500 mg/10 mL
Dostarlimab in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.
[MSHL] Dostarlimab Concentrate For Solution For Infusion 500 mg/10 mL
Monotherapy for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for recurrent or advanced MSI-H or dMMR endometrial cancer.
Dostarlimab in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.
Dostarlimab in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.
Drug Guidance for Subsidy
16/09/2025 Dostarlimab for treating primary advanced or recurrent endometrial cancer
The Ministry of Health’s Drug Advisory Committee has recommended:
Dostarlimab 500 mg concentrate for solution for infusion in combination with platinum-based chemotherapy, followed by dostarlimab as monotherapy, for untreated mismatch repair deficient or microsatellite instability-high primary advanced or recurrent endometrial cancer. Treatment with dostarlimab should be stopped at 3 years, or earlier if disease progresses.
Funding status
[R] Dostarlimab 500 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2025.
[NR] MAF assistance does not apply to untreated mismatch repair proficient or microsatellite stable primary advanced or recurrent endometrial cancer.
Clinical indications, subsidy class and MediShield Life claim limit for dostarlimab are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Jemperli Concentrate For Infusion 500 mg/10 mL |
|